Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | GRM8 | O00222 | 1/20 | 0.44 |
| ▸ | GRM6 | O15303 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL352654 | 1.00 | ALOX5 (0.47) | ALOX5HSD17B10TDP1MEN1CYP2C9 | |
| SCHEMBL352655 | 1.00 | ALOX5 (0.47) | ALOX5HSD17B10TDP1MEN1CYP2C9 | |
| SCHEMBL3976361 | 0.83 | ALOX5 (0.51) | ALOX5SLC1A3SLC1A2SLC1A1LCK | |
| SCHEMBL8255743 | 0.83 | ALOX5 (0.51) | ALOX5SLC1A3SLC1A2SLC1A1LCK | |
| SCHEMBL4603992 | 0.83 | ALOX5 (0.51) | ALOX5SLC1A3SLC1A2SLC1A1LCK | |
| SCHEMBL10821116 | 0.82 | ALOX5 (0.46) | ALOX5SLC1A3SLC1A2SLC1A1LCK | |
| SCHEMBL4603985 | 0.82 | ALOX5 (0.46) | ALOX5SLC1A3SLC1A2SLC1A1LCK | |
| SCHEMBL11694264 | 0.82 | ALOX5 (0.46) | ALOX5CYP2D6SLC6A2SLC6A4SLC1A3 | |
| Hydrochloric Acid SCHEMBL11829834 | 0.80 | ALOX5 (0.45) | ALOX5CYP2D6SLC6A2SLC6A4SLC1A3 | |
| SCHEMBL11431774 | 0.79 | NR1I2 (0.50) | ALOX5TDP1MEN1CYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361273-A1 | METHODS AND COMPOSITIONS | FLAGSHIP PIONEERING INNOVATIONS VII, LLC | 2025-11-27 | — | — | US | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| CN-114269367-A | Therapeutic peptides | 科巴公司 | 2022-04-01 | — | — | CN | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2021067439-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-10329324-B2 | Indoline compounds as granzyme B inhibitors | viDA Therapeutics (CA) | 2019-06-25 | — | — | US | disclosed |
| US-20180057528-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2018-03-01 | — | — | US | disclosed |
| US-9605021-B2 | Indoline compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2017-03-28 | — | — | US | disclosed |
| US-20110117661-A1 | POLYPEPTIDES, SYSTEMS, AND METHODS USEFUL FOR DETECTING GLUCOSE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2011-05-19 | — | — | US | disclosed |
| US-20110117661-A1 | POLYPEPTIDES, SYSTEMS, AND METHODS USEFUL FOR DETECTING GLUCOSE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2011-05-19 | — | — | US | disclosed |
| WO-2009050220-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
| EP-1871776-A2 | FUSED THIENO[2,3-B]PYRIDINE AND THIAZOLO[5,4-B]PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060247320-A1 | Compounds for inhibiting KSP kinesin activity | SCHERING CORPORATION | 2006-11-02 | — | — | US | disclosed |
| WO-2006098961-A2 | FUSED THIENO [2, 3-B] PYRIDINE AND THIAZOLO [5, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2006-09-21 | — | — | WO | disclosed |
| CN-1616432-A | Compound,its use and pharmaceutical compositions comprising same | ELAN PHARM INC (US) | 2005-05-18 | — | — | CN | disclosed |
| CN-1171878-C | Compounds, their use and pharmaceutical compositions containing them | ������˹ҩƷ��˾ | 2004-10-20 | — | — | CN | disclosed |
| CN-1253554-A | Heterocyclic compounds and their use for inhibiting 'beta'-amyloid peptide | ELAN MEDICINE CO (US) | 2000-05-17 | — | — | CN | disclosed |
| CN-1242007-A | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising such compounds, and methods of inhibiting beta amyloid peptide release and/or its synthesis using such compounds | ELAND PHARMACEUTICAL CORP (US) | 2000-01-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | ALOX5 2505/4885HSD17B10 1828/4885TDP1 4591/4885 |
| US-20180057528-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, PRF1, CTSB | ALOX5 1360/4885HSD17B10 2163/4885TDP1 987/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | ALOX5 2505/4885HSD17B10 1828/4885TDP1 4591/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | ALOX5 2505/4885HSD17B10 1828/4885TDP1 4591/4885 |
| US-10329324-B2 | Indoline compounds as granzyme B inhibitors | GZMB, PRF1, CTSB | ALOX5 1360/4885HSD17B10 2163/4885TDP1 987/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | ALOX5 2505/4885HSD17B10 1828/4885TDP1 4591/4885 |
| US-20060247320-A1 | Compounds for inhibiting KSP kinesin activity | KIFC1, KIF5B, KIF2C | ALOX5 4867/4885HSD17B10 1686/4885TDP1 778/4885 |
| US-20110117661-A1 | POLYPEPTIDES, SYSTEMS, AND METHODS USEFUL FOR DETECTING GLUCOSE | IAPP, GCKR, GID4 | ALOX5 4884/4885HSD17B10 3216/4885TDP1 2262/4885 |
| US-20250361273-A1 | METHODS AND COMPOSITIONS | MC4R, GPR119, MC2R | ALOX5 990/4885HSD17B10 811/4885TDP1 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.